EC95 of Remifentanil for Preventing Cough

Drug Usage Clinical Trial

Official title:

Predicted EC95 of Effect-site Concentration of Remifentanil for Preventing Cough After Laryngomicrosurgery From Propofol Anesthesia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02973724
• Other study ID #: AJIRB-MED-CT4-16-349
• Status: Completed
• Phase: N/A
• First received: November 21, 2016
• Last updated: June 8, 2017
• Start date: November 2016
• Est. completion date: June 2017

Study information

• Verified date: June 2017
• Source: Ajou University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigator designed this study to investigate remifentanil effect-site concentration in 95% of patients (EC95) for preventing cough after laryngomicrosurgery from propofol anesthesia.

Description:

At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). Extubation was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: June 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years to 65 Years

Eligibility

Inclusion Criteria:

• ASA I-II patients undergoing general anesthesia for laryngomicrosurgery

Exclusion Criteria:

• Anticipated difficult airway

• COPD, Asthma

• Recent URI (< 2 weeks)

• Severe cardiac, hepatic renal disease

Related Conditions & MeSH terms

• Drug Usage

Intervention

Drug:
• Remifentanil
The concentration of remifentanil was determined by biased-coin up and down design, starting from 1.0 ng/ml (0.4 ng/ml as a step size)
• Propofol anesthesia
Anesthesia was induced with propofol target-controlled infusion at an effect-site concentration of 5.0 µg/ml.

Locations

Country	Name	City	State
Korea, Republic of	Ajou University Hospital	Suwon	Gyeonggi-do

Sponsors (1)

Lead Sponsor	Collaborator
Ajou University School of Medicine

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of cough	Number of cough or a strong and sudden contraction of the abdomen during periextubation periods	from end of surgery to 5 min after tracheal extubation